Anti-NKG2A Antibody, Non-Fucosylated (BioBet-1150ZP) (CAT#: BioBet-1150ZP) Datasheet

KLRC1

killer cell lectin-like receptor subfamily C, member 1

Natural killer (NK) cells are lymphocytes that can mediate lysis of certain tumor cells and virus-infected cells without previous activation. They can also regulate specific humoral and cell-mediated immunity. The protein encoded by this gene belongs to the killer cell lectin-like receptor family, also called NKG2 family, which is a group of transmembrane proteins preferentially expressed in NK cells. This family of proteins is characterized by the type II membrane orientation and the presence of a C-type lectin domain. This protein forms a complex with another family member, KLRD1/CD94, and has been implicated in the recognition of the MHC class I HLA-E molecules in NK cells. The genes of NKG2 family members form a killer cell lectin-like receptor gene cluster on chromosome 12. Multiple alternatively spliced transcript variants encoding distinct isoforms have been observed.

KLRC1; killer cell lectin-like receptor subfamily C, member 1; NKG2; NKG2A; CD159A; NKG2-A/NKG2-B type II integral membrane protein; NK cell receptor A; C-lectin type II protein; natural killer cell lectin; natural killer group protein 2; NKG2-1/B activating NK receptor; NKG2-A/B-activating NK receptor; CD159 antigen-like family member A; NKG2-A/B type II integral membrane protein

Membrane

Diseases associated with KLRC1 include Bare Lymphocyte Syndrome, Type I and Trichohepatoenteric Syndrome 1.

Its related pathways are Immune response Role of DAP12 receptors in NK cells and Hematopoietic Stem Cells and Lineage-specific Markers.

Plays a role as a receptor for the recognition of MHC class I HLA-E molecules by NK cells and some cytotoxic T-cells.

1.Glycosylation at Asn102, Asn103, Asn151, and Asn180 2.Modification sites at PhosphoSitePlus

Protein Based Therapies
Monoclonal antibody (mAb)

IgG4

BioBet-1150ZP

Humanized

Human

IPH2201 is a first-in-class humanized IgG4 targeting NKG2A receptors expressed on tumor infiltrating cytotoxic NK and CD8 T lymphocytes. IPH2201 may re-establish a broad anti-tumor response mediated by NK and T cells. IPH2201 may also enhance the cytotoxic potential of other therapeutic antibody. IPH2201 is currently in Phase II development in various cancer indications and combinations.

Autoimmune Diseases; Inflammatory Diseases; Rheumatoid Arthritis

Autoimmune Diseases; Inflammatory Diseases; Rheumatoid Arthritis